Cesca Therapeutics announces commercial launch of its AXP II blood system

red blood cells
Cesca Therapeutics announces the commercial launch of its AXP II blood system.

Cesca Therapeutics, which specializes in regenerative medicine and offers a range of automated technologies for cell-based therapeutics, has announced the commercial launch of its AXP II system.

The AXP II, which was developed by Cesca’s device division ThermoGenesis, is designed to collect, isolate and store hematopoietic stem cell concentrates from cord blood and peripheral blood.

“Our first generation AXP system consistently achieves stem cell recovery rates in excess of 97%, the highest in the industry,” Chris Xu, Cesca’s chief executive, said in a statement. “With AXP II, we are introducing important enhancements to the AXP device, docking station, and proprietary XpressTRAK software that together represent the biggest advancement in automated cord blood processing in many years.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The company, which went public late last year, acquired SynGen in a deal announced in July that gave Cesca SynGen’s cell processing platform technology. 

Suggested Articles

Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division.

A new digital health startup is exiting stealth mode with its advanced, long-lasting patient monitoring device—and touting a quick FDA clearance.

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.